Dexamethasone intravitreal implant in the treatment of diabetic macular edema

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 1321-1335

  Dugel, Pravin U ^a,b   Bandello, Francesco ^c   Loewenstein, Anat ^d  

^a RETINAL CONSULTANTS OF ARIZONA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Corticosteroids; Dexamethasone; Diabetic retinopathy; Implant; Intravitreal; Macular edema

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; TRIAMCINOLONE ACETONIDE;

BEST CORRECTED VISUAL ACUITY; CATARACT; CHEMOSIS; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; DEVICE SAFETY; DIABETIC MACULAR EDEMA; DRUG EFFECT; DRUG EFFICACY; DRUG IMPLANT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; ENDOPHTHALMITIS; HUMAN; IMPLANT FRACTURE; INTRAOCULAR HYPERTENSION; LOW LEVEL LASER THERAPY; MACULAR FIBROSIS; MEDICAL DEVICE COMPLICATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; RETINA TEAR; RETINOPATHY; REVIEW; SUSTAINED DRUG RELEASE; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

EID: 84937696358     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S79948     Document Type: Review

References (92)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464–1474.
2. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic macu­lopathy. Semin Ophthalmol. 1999;14(4):223–232.
3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32.
4. Yau JW, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564.
5. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open. 2013;3(3):e002269.
6. Zhang W, Liu H, Al-Shabrawey M, Caldwell RW, Caldwell RB. Inflam­mation and diabetic retinal microvascular complications. J Cardiovasc Dis Res. 2011;2(2):96–103.
7. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular fac­tors contribute to this pathological process. Acta Ophthalmol. 2010;88(3):279–291.
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progres­sion of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with con­ventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
10. Antonetti DA, Barber AJ, Bronson SK, et al; JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55(9):2401–2411.
11. Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. General pathophysiology of macular edema. Eur J Ophthalmol. 2011;21(suppl 6):S10–S19.
12. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012;12(4):364–375.
13. Zhang W, Liu H, Rojas M, Caldwell RW, Caldwell RB. Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy. 2011;3(5):609–628.
14. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitre­ous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73–79.
15. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12):e8158.
16. El-Asrar AM, Nawaz MI, Kangave D, et al. High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis. 2011;17:1829–1838.
17. Adamiec-Mroczek J, Oficjalska-Mlyńczak J, Misiuk-Hojło M. Roles of endothelin-1 and selected proinflammatory cytokines in the pathogen­esis of proliferative diabetic retinopathy: analysis of vitreous samples. Cytokine. 2010;49(3):269–274.
18. Maier R, Weger M, Haller-Schober EM, et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis. 2008;14:637–643.
19. Lee WJ, Kang MH, Seong M, Cho HY. Comparison of aqueous concen­trations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol. 2012;96(11):1426–1430.
20. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol. 1999;14(4):233–239.
21. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47(suppl 2):S253-S262.
22. Joussen AM, Poulaki V, Le ML, et al. A central role for inflamma­tion in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450–1452.
23. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343–358.
24. Brucklacher RM, Patel KM, VanGuilder HD, et al. Whole genome assessment of the retinal response to diabetes reveals a progres­sive neurovascular inflammatory response. BMC Med Genomics. 2008;1:26.
25. Joussen AM, Poulaki V, Mitsiades N, et al. Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 2003;17(1):76–78.
26. Rojas M, Zhang W, Xu Z, et al. Requirement of NOX2 expression in both retina and bone marrow for diabetes-induced retinal vascular injury. PLoS One. 2013;8(12):e84357.
27. Deissler HL, Deissler H, Lang GK, Lang GE. VEGF but not PlGF disturbs the barrier of retinal endothelial cells. Exp Eye Res. 2013;115:162–171.
28. Aveleira CA, Lin CM, Abcouwer SF, Ambrosio AF, Antonetti DA. TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes. 2010;59(11):2872–2882.
29. Leal EC, Manivannan A, Hosoya K, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48(11):5257–5265.
30. Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol. 1999;14(4):240–248.
31. Barber AJ, Antonetti DA. Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci. 2003;44(12):5410–5416.
32. Bolton SJ, Anthony DC, Perry VH. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood–brain barrier breakdown in vivo. Neuroscience. 1998;86(4):1245–1257.
33. Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflam­mation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19(1):52–59.
34. Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmo­logica. 2010;224(suppl 1):25–30.
35. Clark AR, Belvisi MG. Maps and legends: the quest for dissoci­ated ligands of the glucocorticoid receptor. Pharmacol Ther. 2012;134(1):54–67.
36. Busillo JM, Cidlowski JA. The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab. 2013;24(3):109–119.
37. Solito E, Mulla A, Morris JF, Christian HC, Flower RJ, Buckingham JC. Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Endocrinology. 2003;144(4):1164–1174.
38. Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M. Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood. 2008;112(6):2512–2519.
39. Logie JJ, Ali S, Marshall KM, Heck MM, Walker BR, Hadoke PW. Glucocorticoid-mediated inhibition of angiogenic changes in human endothelial cells is not caused by reductions in cell proliferation or migration. PLoS One. 2010;5(12):e14476.
40. Gong Y, Jin X, Wang QS, et al. The involvement of high mobility group 1 cytokine and phospholipases A2 in diabetic retinopathy. Lipid Health Dis. 2014;13:156.
41. Lupo G, Motta C, Giurdanella G, et al. Role of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studies. Biochem Pharmacol. 2013;86(11):1603–1613.
42. Pannicke T, Iandiev I, Wurm A, et al. Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes. 2006;55(3):633–639.
43. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corti­costeroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–1444.
44. Miura Y, Roider J. Triamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):641–649.
45. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A. Muller cells as players in retinal degeneration and edema. Graefes Arch Clinical Exp Ophthalmol. 2007;245(5):627–636.
46. Zhao M, Bousquet E, Valamanesh F, et al. Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexametha­sone in the healthy and inflamed retina. Invest Ophthalmol Vis Sci. 2011;52(9):6340–6347.
47. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and sys­temic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57(14):2010–2032.
48. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Oph­thalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51(11):5403–5420.
49. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47(suppl 1):S41–S52.
50. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 2007;39(5):244–254.
51. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitre­ous injection: a comprehensive review. Retina. 2004;24(5):676–698.
52. Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110(2):259–266.
53. Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014;193:100–112.
54. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 2004;23(3):253–281.
55. Moisseiev E, Regenbogen M, Rabinovitch T, Barak A, Loewenstein A, Goldstein M. Evaluation of pain during intravitreal Ozurdex injections vs intravitreal bevacizumab injections. Eye. 2014;28(8):980–985.
56. Meyer CH, Klein A, Alten F, et al. Release and velocity of micron­ized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera. Retina. 2012;32(10):2133–2140.
57. Berarducci A, Sian IS, Ling R. Inadvertent dexamethasone implant injection into the lens body management. Eur J Ophthalmol. 2014;24(4):620–622.
58. Coca-Robinot J, Casco-Silva B, Armada-Maresca F, Garcia-Martinez J. Accidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens. Eur J Ophthalmol. 2014;24(4):633–636.
59. Fasce F, Battaglia Parodi M, Knutsson KA, et al. Accidental injection of dexamethasone intravitreal implant in the crystalline lens. Acta Ophthalmol. 2014;92(4):e330–e331.
60. Agrawal R, Fernandez-Sanz G, Bala S, Addison PK. Desegmentation of Ozurdex implant in vitreous cavity: report of two cases. Br J Oph­thalmol. 2014;98(7):961–963.
61. Donmez O, Parlak M, Yaman A, Saatci AO. Splitting of a dexametha­sone implant (Ozurdex) following the injection. Case Rep Ophthalmol Med. 2013;2013:247949.
62. Roy R, Hegde S. Split Ozurdex implant: a caution. Can J Ophthalmol. 2013;48(1):e15–e16.
63. Rishi P, Mathur G, Rishi E. Fractured Ozurdex™ implant in the vitreous cavity. Ind J Ophthalmol. 2012;60(4):337–338.
64. Wai Ch’ng S, Padroni S, Banerjee S. Anterior vitreous displace­ment of the intravitreal dexamethasone implant (Ozurdex). Eye. 2014;28(2):238–239.
65. Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and manage­ment strategies. Ophthalmology. 2014;121(1):67–71.
66. Kishore SA, Schaal S. Management of anterior chamber dislocation of dexamethasone implant. Ocul Immunol Inflamm. 2013;21(1):90–91.
67. Vela JI, Crespi J, Andreu D. Repositioning of dexamethasone intra­vitreal implant (Ozurdex) migrated into the anterior chamber. Intl Ophthalmol. 2012;32(6):583–584.
68. Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A. Wander­ing Ozurdex(®) implant. J Ophthalmic Inflamm Infect. 2012;2(1):1–5.
69. Malclès A, Janin-Manificat H, Yhuel Y, et al. [Anterior chamber migra­tion of intravitreal dexamethasone implant (Ozurdex®) in pseudophakic eyes: report of three cases]. J Franc Ophtalmol. 2013;36(4):362–367. French.
70. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80–86.
71. Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvit­rectomized eyes. Invest Ophthalmol Vis Sci. 2011;52(7):4605–4609.
72. Weijtens O, Feron EJ, Schoemaker RC, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128(2):192–197.
73. Weijtens O, van der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol. 1997;123(3):358–363.
74. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002;109(10):1887–1891.
75. Weijtens O, Schoemaker RC, Cohen AF, et al. Dexamethasone concen­tration in vitreous and serum after oral administration. Am J Ophthalmol. 1998;125(5):673–679.
76. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intra­vitreal triamcinolone acetonide between vitrectomized and nonvitrec­tomized eyes. Retina. 2005;25(5):556–560.
77. Haller JA, Kuppermann BD, Blumenkranz MS, et al; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intrav­itreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128(3):289–296.
78. Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, Blumenkranz MS. Intravitreous dexamethasone effects on differ­ent patterns of diabetic macular edema. Arch Ophthalmol. 2010;128(5):642–643.
79. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocu­lar concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681–686.
80. Boyer DS, Faber D, Gupta S, et al; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–923.
81. Callanan DG, Gupta S, Boyer DS, et al; Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120(9):1843–1851.
82. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914.
83. Danis RP, Sadda S, Cui H, Li X-Y, Hashad Y, Whitcup SM. Anatomic outcomes with dexamethasone intravitreal implant in diabetic macular edema: a pooled analysis of two randomized Phase III trials. ARVO 2014 Annual Meeting; May 4–8, 2014, Orlando, FL.
84. Sadda S, Danis RP, Li X-Y, Cui H, Hashad Y, Whitcup SM. Anatomic effects of dexamethasone intravitreal implant in diabetic macular edema: pooled analysis of findings from two randomized Phase 3 studies. 32nd Annual Meeting of the American Society of Retina Specialists; August 9–13, 2014; San Diego.
85. Lazic R, Lukic M, Boras I, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014;34(4):719–724.
86. Sorkin N, Loewenstein A, Habot-Wilner Z, Goldstein M. Intravitreal dexamethasone implant in patients with persistent macular edema of variable etiologies. Ophthalmologica. 2014;232(2):83–91.
87. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231(3):141–146.
88. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intra­vitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema. Clin Ophthalmol. 2013;7:1423–1428.
89. Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthal­mologica. 2012;228(2):117–122.
90. Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011;129(7):914–920.
91. Anon. Ozurdex Prescribing Information; 2014. Available from: http://www.allergan.com/assets/pdf/ozurdex_pi.pdf. Accessed March 27, 2015.
92. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132.